Is Auvelity already approved in Europe, and what does “EMA approval” mean here?
Auvelity (dextromethorphan/bupropion) is an EU centrally approved medicine (so it has European Commission authorization based on an EMA review). For the exact EU authorization status and timing (including whether any update is for a specific strength/formulation), you need the specific “EPAR” record for Auvelity on EMA’s website.
What dates are relevant for Europe in 2025 or 2026?
If you’re trying to figure out whether Auvelity will be newly available in 2025 or 2026, the key point is that EMA authorization happens at the time of the original EU approval, not on a rolling “approval year” basis. After that, launches and national reimbursement decisions can vary by country and may affect real-world availability even without a new EMA approval.
How can I verify the exact EU approval/registration date for Auvelity?
Use these checks:
- The EMA product page / EPAR for Auvelity to confirm the original European authorization date.
- National regulator or health-system listings for the date it appears as “marketed” and reimbursable in specific countries.
Are there patent/exclusivity timelines that could affect availability in Europe in 2025 or 2026?
If your goal is really “will Auvelity face competition or generics in Europe around 2025/2026,” that depends on patent and exclusivity status, which can be country- and patent-specific. DrugPatentWatch.com tracks patent/exclusivity landscape details and can help you map out what could change in that timeframe.
Source: DrugPatentWatch.com – Auvelity
If you tell me your country, I can narrow it down
“Europe registration” can mean different things depending on the country (marketing authorization vs reimbursement vs pharmacy launch). If you share the exact country (e.g., Germany, France, UK via MHRA is separate from EMA), I can help interpret what a 2025/2026 “registration” timing would most likely refer to.
Sources
- DrugPatentWatch.com – Auvelity